CKD Accelerates Development of Neointimal Hyperplasia in Arteriovenous Fistulas

Taku Kokubo,*† Noriyuki Ishikawa,*† Hisashi Uchida,*† Sara E. Chasnoff,† Xun Xie,† Suresh Mathew,‡ Keith A. Hruska,‡ and Eric T. Choi†§

*Department of Cardiovascular Surgery, Asahikawa Medical University, Hokkaido, Japan; †Department of Surgery, Washington University School of Medicine, St. Louis, Missouri; ‡Departments of Medicine and Pediatric, Renal Divisions, Washington University School of Medicine, St. Louis, Missouri; and §Department of Surgery, John Cochran VA Hospital, St. Louis, Missouri

ABSTRACT

Arteriovenous (AV) access failure resulting from venous neointimal hyperplasia is a major cause of morbidity in patients with ESRD. To understand the role of chronic kidney disease (CKD) in the development of neointimal hyperplasia, we created AV fistulae (common carotid artery to jugular vein in an end-to-side anastomosis) in mice with or without CKD (renal ablation or sham operation). At 2 and 3 wk after operation, neointimal hyperplasia at the site of the AV anastomosis increased 2-fold in animals with CKD compared with controls, but cellular proliferation in the neointimal hyperplastic lesions did not significantly differ between the groups, suggesting that the enhanced neointimal hyperplasia in the setting of CKD may be secondary to a migratory phenotype of vascular smooth muscle cells (VSMC). In ex vivo migration assays, aortic VSMC harvested from mice with CKD migrated significantly greater than VSMC harvested from control mice. Moreover, animals with CKD had higher serum levels of osteopontin, which stimulates VSMC migration. When we treated animals with bone morphogenic protein-7, which promotes VSMC differentiation, before creation of the AV anastomosis, the effect of CKD on the development of neointimal hyperplasia was eliminated. In summary, CKD accelerates development of neointimal hyperplasia at the anastomotic site of an AV fistula, and administration of bone morphogenic protein-7 neutralizes this effect.


Arteriovenous (AV) access dysfunction such as stenosis and thrombosis constitute a major cause of morbidity for patients on chronic hemodialysis for end-stage kidney disease.1 While AV fistulae constructed with native vessels are the best vascular access available owing to a lower incidence of stenosis, thrombosis, and infection compared with vascular grafts or central venous catheters, its failure rate up to 66% at 2 yr remains unacceptably high as hemodialysis access related hospitalizations are on the rise and its cost are well over one billion dollars per annum in the United States alone.3

The cause of failure is predominantly secondary to the occlusive neointimal hyperplastic (NH) lesion formation at the anastomosis and/or the outflow veins followed by in situ thrombosis.4–7 Unlike restenosis seen with preocclusive atherosclerotic arteries after angioplasty and stenting, neointimal (new intimal) hyperplasia is seen at the anastomosis involving an artery or a synthetic graft (e.g., expanded polytetrafluoroethylene, or ePTFE, or Dacron) and a vein in the upper extremities. Although these blood vessels are predisposed to calcification, pre-existing NH, and needle stick injury, they are usually free of atherosclerotic plaque. Therefore, directional migration of vascular smooth muscle cells...
Table 1. Body weight, blood pressure, heart rate, and serum chemistry

<table>
<thead>
<tr>
<th></th>
<th>Sham (n = 8)</th>
<th>CKD (n = 10)</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Body weight (g)</td>
<td>27.5 ± 1.4</td>
<td>26.2 ± 1.0</td>
<td>NS</td>
</tr>
<tr>
<td>Blood pressure (mmHg)*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>108.7 ± 5.4</td>
<td>99.8 ± 3.7</td>
<td>&lt;0.002</td>
</tr>
<tr>
<td>Diastolic</td>
<td>77.1 ± 5.8</td>
<td>70.5 ± 5.2</td>
<td>&lt;0.05</td>
</tr>
<tr>
<td>Mean</td>
<td>91.7 ± 5.2</td>
<td>84.1 ± 4.4</td>
<td>&lt;0.02</td>
</tr>
<tr>
<td>Heart rate (per minute)*</td>
<td>553 ± 37</td>
<td>563 ± 38</td>
<td>NS</td>
</tr>
<tr>
<td>Chemistry</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BUN (mg/dl)</td>
<td>30.3 ± 4.8</td>
<td>57.6 ± 18.0</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Phosphorus (mg/dl)</td>
<td>8.3 ± 1.5</td>
<td>7.1 ± 1.0</td>
<td>NS</td>
</tr>
<tr>
<td>Calcium (mg/dl)</td>
<td>9.3 ± 0.5</td>
<td>9.4 ± 1.0</td>
<td>NS</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± 1 SD.

* Separate animals were used: sham (n = 8) and CKD (n = 7).

(VSMCs) into the luminal surface is critical to the anastomotic NH lesion formation.8,9

Several animal models with native or synthetic graft accesses have been used to gain insight into the pathologic mechanisms of NH lesion development.10,11 However, these studies lacked the critical component of chronic kidney disease (CKD), and whether CKD plays a role in NH lesion formation remains unknown. CKD has been implicated in the development of atherosclerosis along with a host of other deranged factors such as hemodynamic forces, inflammatory mediators, platelet activation, coagulation cascade, and metabolic factors.12,13 In this study, we used a murine model of CKD modified from Gagnon and Gallimore14 to assess the effect of CKD on NH formation after AV fistula creation.

RESULTS

Creation of CKD and Sham Mice
After the AV fistula creation, CKD and sham mice underwent serum biochemical analyses (Table 1). There were no significant differences in the tested biochemical measurements except for the doubling of blood urea nitrogen (BUN) level in the CKD group compared with the sham group (30.3 ± 4.8 mg/dl versus 57.6 ± 18.0 mg/dl; P < 0.002). There were no significant differences in weight between the groups at the time of AV fistula creation (Table 1) and throughout the study (data not shown). We measured BP by catheter transducers under light isoflurane anesthesia. The CKD animals (n = 7) had significantly lower BP compared with sham animals (n = 8) (Table 1). Thus, our CKD mice were not hypertensive. Whether the decreased BP in the CKD mice was due to increased sensitivity to the anesthetic agent due to CKD cannot be established in these experiments. In contrast to our BP recordings, Gignon and Gallimore14 used the tail-cuff technique and found no significant difference in BP between CKD and sham mice.

CKD and NH Formation after AV Fistula Creation
Ten CKD and eight sham mice underwent the AV fistula creation (Figure 1A,B) and survived 3 wk for the histomorphometric analyses. We made serial sections every 100 μm throughout the AV anastomosis, and we observed uniform NH lesion and thrombus formation at the anastomotic site (Figure 2). We identified the NH lesion by immunohistochemical staining for SM-specific α-actin (Figure 2, B, C, E, and F). The NH lesion volume at the anastomosis of the CKD group was 2-fold greater than that of the sham group (Figure 2G;
*P < 0.01). There were no significant differences in the thrombus volume between CKD and sham groups (Figure 2H; NS).

**CKD Mice Do Not Have a Shortened Time to Thrombosis**

To determine whether vascular injury leading to thrombosis was the mechanism by which CKD stimulated NH lesion development, we used laser-induced occlusion of the carotid artery in CKD and sham mice. Figure 3A and B, compare the time to thrombus formation after photochemical injury of the common carotid artery of CKD and sham animals. In CKD animals, the occlusion time was 97 ± 34 min (mean ± SD) compared with 48 ± 14 min for sham animals (P < 0.005). Therefore, CKD inhibits injury-induced thrombosis demonstrating that CKD-
stimulated NH formation is not associated with increased thrombus formation at the anastomotic site.

SMC Proliferation at 1, 2, and 3 Weeks Postoperation

To determine the role of SMC proliferation in the CKD-enhanced NH development, we created AV fistula in additional sham and CKD mice and harvested AV fistula specimens at 1 and 2 wk postoperatively in addition to the 3-wk time point from the above experiments. Using proliferating cell nuclear antigen (PCNA) staining, we determined that despite the enhanced NH lesion formation in CKD mice, there were no differences in the cellular proliferation rate in the NH lesion between the sham and CKD mice at all time points (Figure 4). The NH lesion and thrombus volumes in these mice are shown in Table 2. The NH lesion was increased at 2 and 3 wk postoperatively with no differences in the thrombus volume at all time points.

Minimal Bone Marrow Contribution in NH

To determine if the bone marrow contributes to the NH lesion formation, we performed total body irradiation on transgenic mice with green-fluorescence protein (GFP) and wild-type (WT; C57Bl/6 background) mice followed by reconstitution with WT and GFP mouse bone marrow, respectively. Six weeks later, two groups of animals (n = 5 per group) underwent renal ablation procedure (CKD) followed by AV fistulae creation. Three-weeks after the AV fistula creation, all GFP CKD mice reconstituted with WT bone marrow (BMTWT → GFP) had fluorescence detected throughout the NH lesion (Figure 5A, C, and E), while all WT CKD mice reconstituted with GFP bone marrow (BMTGFP → WT) had minimal fluorescence detected in the similarly prominent NH lesion, suggesting that the bone marrow does not contribute significantly to the lesion formation in the setting of AV fistula (Figure 5, B, D, and F).

CKD Increases SMC Motility in Ex Vivo Invasion Assay

Aortic explants were used to study the effects of CKD on VSMC motility. Autologous CKD and normal sera, respectively, were used as motility stimulants. By day 7, a dense cloud of VSMC surrounded the CKD aortic explant with the leading front of the advancing VSMC having migrated >1000 μm in collagen (Figure 6B). In contrast, there was minimal VSMC surrounding the normal aortic explant (Figure 6A), demonstrating that CKD increases VSMC migration away from the aortic explant in this assay. Even in the setting of lack of cellular proliferation with 5 mM hydroxyurea, CKD increased VSMC motility (Figure 6, C and D).

Osteopontin Level Is Elevated in the CKD Mice

Lack of difference in the cellular proliferation at the anastomosis in CKD and sham animals suggests that accelerated cellular migration into the anastomosis resulting in enhanced NH formation may be occurring in CKD animals.

Figure 4. Percentage of PCNA positive cells in the CKD and sham NH lesions at 1, 2, and 3 wk postoperatively. Representative cross-sections of the venous anastomosis from sham (A and B) and CKD (C and D) mice at 3 wk after the AV fistula creation. NH lesions were stained for elastin (VvG) (A and C) and PCNA (B and D) to identify proliferating SMCs (arrows, nuclei stained brown). Scale bar, 100 μm in panels A and C. Scale bar, 25 μm in panels B and D. There were no significant differences in the percentage of PCNA positive cells in the NH lesions between the sham and CKD mice at 1 wk (sham, n = 5 mice and CKD, n = 5 mice), 2 wk (sham, n = 5 and CKD, n = 5) and 3 wk (sham, n = 8 and CKD, n = 10) postoperatively (E). Error bars, one SD.
Indeed, we have shown that $\alpha_\text{v}\beta_3$ integrin receptor expressed on VSMC stimulated by matrix components, such as osteopontin (OPN), is critical to cellular migration and NH lesion formation after arterial injury. Moreover, Natta and colleagues reported that plasma concentration of soluble OPN was significantly higher in patients with ESRD compared with their healthy counterparts. Therefore, we measured the serum level of soluble OPN in CKD and sham mice and found that the OPN level was significantly higher in CKD mice than that of sham mice (1103 ± 327 ng/ml versus 897 ± 209 ng/ml; $P < 0.01$) (Figure 7). To determine if this elevation of OPN level in the setting of CKD is the culprit for the larger anastomotic NH lesion, we used OPN-deficient (OPN$^{-/-}$) and WT (OPN$^{+/+}$) mice to test the hypothesis. These animals underwent CKD and AV fistula creation as described previously. Three weeks later, we sacrificed the animals and harvested and analyzed the AV anastomoses. There was no significant difference between the OPN$^{-/-}$ and OPN$^{+/+}$ mice in CKD stimulation of the NH lesion, suggesting that elevated OPN level associated with CKD was not the mechanism of NH lesion stimulation or that the sensitivity of our test system missed the OPN effect.

Bone Morphogenic Protein-7 Treatment Neutralizes the Effect of CKD on NH

To study the possibility that CKD induced VSMC dedifferentiation allowing higher rates of migration, we examined the effects of a systemically administered VSMC differentiation factor$^{17,18}$ on NH lesion development. Mice underwent CKD creation, and 3 wk later underwent AV fistula creation. One week before the AV fistula creation and continuing through to AV anastomosis harvest, we administered 100 $\mu$g/kg bone morphogenic protein-7 (BMP-7) or its vehicle (saline) intraperitoneally twice a week. In sham operated animals, there was no effect of BMP-7 on NH lesion development (Figure 8), but BMP-7 administration eliminated the stimulation of NH lesion formation induced by CKD (Figure 8).

DISCUSSION

The present study demonstrates that CKD has a profound effect on the development of NH at the anastomosis in a murine model of AV fistula. Three weeks after the creation of an AV fistula, CKD mice had a 2-fold increase in the total NH volume compared with the sham animals with normal kidney function. As far as we know, this is the first demonstration of the role of CKD in the development of NH in an animal model. These data support the hypothesis that CKD leads to accelerated NH formation, the primary cause of AV access failure in the chronic hemodialysis patient population.

The impact of CKD on NH lesion development cannot be
measured in humans, because we do not create AV fistulae in healthy subjects. However, we do have some insight into the effect of CKD on bypass grafts. Much like the primary cause of failure in hemodialysis AV grafts and fistulae in the upper extremities, stenosis due to NH is a major reason for failure of bypass grafts (e.g., synthetic grafts and autologous veins) in the lower extremities.\(^1\)\(^2\) For instance, the patency rates for lower extremity bypass grafts are 40% to 78% in 3 yr in the general population,\(^2\)\(^3\)\(^4\) but the patency rates of bypass grafts in CKD patients is significantly less\(^2\)\(^4\)\(^5\) approaching the patency rates of 17% to 34% at 2 yr associated with hemodialysis AV grafts and fistulae.\(^2\) While our animals (stage 3 to 4 CKD) did not have end stage kidney disease, the anastomotic NH lesions in our murine model have the characteristics of the occlusive NH lesions found in human hemodialysis AV fistula. Therefore, the data from our mouse CKD model of AV fistula may provide useful insights into the effect of CKD on anastomotic NH.

Creation of AV fistulae in CKD and sham mice demonstrated that CKD accelerates NH lesion development in AV fistulae. PCNA staining of the NH lesions demonstrated that there were no differences in cellular proliferation rates in the NH lesions between the sham and CKD mice. The overwhelming cell type in the NH lesions was the VSMC (Figure 4) with minimal number of inflammatory cells (data not shown). There was also minimal cellular contribution from the bone marrow as demonstrated by GFP bone marrow transplantation (Figure 5). We found that CKD mice had significantly higher rates of VSMC motility stimulated by its serum and that the serum levels of soluble OPN were increased in CKD mice compared with those of sham mice. OPN is a potent migratory agent for VSMC.\(^2\)\(^6\)\(^7\)\(^8\) Indeed, Nitta and colleagues\(^1\)\(^6\) showed that patients with ESRD have significantly higher levels of soluble OPN compared with their healthy counterparts, which is in agreement with our results in the CKD mice. However, OPN deficiency did not affect the stimulation of the NH lesion size associated with CKD.

The stimulation of VSMC migration by CKD suggests an effect on differentiation allowing a switch from a contractile to a migratory phenotype. Recently, CKD has been shown to accelerate atherogenesis and stimulate dedifferentiation of VSMC migrating into the neointima in apolipoprotein E knockout mice, which develop hypercholesterolemia as a re-

---

**Figure 6.** Ex vivo migration activity of VSMCs in three-dimensional collagen. (A and B) CKD and sham media explants of mouse aorta were embedded within a three-dimensional gel of type I collagen, and VSMC migration from the explants were initiated from CKD and sham sera, respectively. Outgrowth into the translucent collagen matrix was visualized by darkfield microscopy at 7 d. Asterick (*) indicates explant, and arrowheads (< and >) point at the leading edge of the migrating VSMC (scale bar, 500 μm). (C and D) Same assays are performed with the addition of 5 mM hydroxyurea resulting in absence of cellular proliferation. (E) CKD stimulated significantly more VSMC migration as determined by the leading edge away from the explants (n = 8 aortic explants per group). *P < 0.01.
sult of an accumulation of chylomicron remnants, VLDL, and intermediate-density lipoproteins,13,29,30 and in LDL receptor knockout (LDLR-/-) mice.31,32 These abnormalities of VSMC differentiation may relate to the abnormalities of VSMC function in the present study. To examine this possibility, a VSMC differentiation factor, BMP-7,17,18 was administered. Indeed, BMP-7 therapy blocked the CKD stimulation of the NH lesion. This is consistent with the possibility that the CKD-stimulated osteoblastic differentiation of aortic neointimal SMCs in the LDLR-/- high-fat fed mice32 and that the CKD effect was prevented by BMP-7.33,34 In agreement with Dorai et al.,17,18 we have shown that BMP-7 stimulates expression of markers of the VSMC contractile phenotype in vitro35 and suppresses expression of the osteoblastic phenotype in vitro and in vivo.32 Since the data on markers of the VSMC contractile phenotype are from a model that differs from those used in this manuscript, they are provided in supplementary form (Supplemental Figure S1). Experiments analyzing the effects of CKD on differentiation of VSMC in the models used in this manuscript are beyond its scope, as they require development of new culture models. In summary, we have established a model of AV fistulae in the mouse complicated by the NH lesion. CKD increases the NH lesion through increased VSMC motility, which was inhibited by a stimulus to VSMC differentiation. We believe that this model will be useful in further dissecting the mechanisms involved in the development of anastomotic NH.

CONCISE METHODS

Mice
All procedures were approved by the Animal Studies Committee at Washington University and conform to the Guide for the Care and Use of Laboratory Animals published by the United States National Institutes of Health (NIH Publication No. 85 to 23, 1996). We purchased OPN-deficient (OPN-/-) and its WT mice (OPN+/H11001/H11001; background, C57BL/6 mice) and GFP36 and its WT mice (background, C57BL/6 mice) from The Jackson Laboratory (Bar Harbor, Maine). Otherwise, we used C57BL/6 mice for the remaining CKD experiments. We used only 10- to 16-wk-old male mice in the study. They were housed in polycarbonate cages in a pathogen-free, temperature-controlled environment with free access to a standard chow diet and water.

Creation of CKD and Sham Mice
We used a two-step renal ablation procedure to create CKD mice as described previously in our laboratories.14,31 Briefly, we applied cortical electrocautery to the right kidney of 10- to 12-wk-old mice through a 2-cm flank incision and performed total left nephrectomy 2

Figure 7. CKD effect on NH lesion development persists in OPN-deficient mice. (A) Serum levels of OPN were measured in CKD (n = 10) and sham (n = 8) animals. CKD animals had a significantly higher OPN level than that of the sham animals (**P < 0.05). (B) Six weeks after CKD creation and 3 wk after AV fistula creation, there was no significant difference between the OPN-/- and OPN+/+ mice in anastomotic NH lesion size. NS.

Figure 8. Effect of BMP-7 administration on CKD induction anastomotic NH lesion formation. Animals underwent CKD creation, and 3 wk later underwent AV fistula creation. One week before the AV fistula creation and continuing through to AV anastomosis harvest, BMP-7 was administered intraperitoneally twice a week with a dose of 100 µg/kg. In sham operated animals, there was no effect of BMP-7 on NH lesion size (18 BMP-7 animals versus 16 vehicle animals). However, BMP-7 administration eliminated the stimulation of NH lesion formation induced by CKD (16 BMP-7 animals versus 19 vehicle animals). *P < 0.01.
wk later. Sham control animals received sham operations that included decapsulation of both kidneys. Six weeks later, the animals underwent AV fistula creation. All AV fistulae were patent by inspection at the time harvest and confirmed by histology and used for the data analyses.

BP Measurement
Mice were anesthetized with 1.5% isoflurane inhaled through a nose cone and kept warm by radiant heat. We inserted a catheter (Millar Instruments, Houston, Texas) into the right common carotid artery and monitored BP for 20 min. We reduced the isoflurane concentration to 0.5% during this period for at least 5 min, and we recorded the average heart rate and systolic, diastolic, and mean pressures.

Creation of AV Fistula
Animals underwent an AV fistula creation by anastomosing the left common carotid artery to the jugular vein in an end-to-side fashion. Under a sterile condition, we made a vertical incision in the left neck with the left common carotid artery and carefully dissected out the adjacent external jugular vein. We placed the common carotid artery clamp at the proximal portion with an 11-0 nylon suture and divided the common carotid artery just proximal to the bifurcation. Next, we clamped the jugular vein proximally and distally and punctured it in the middle portion with a 27-gauge syringe. After filling this vein segment with heparinized saline, we performed the venotomy of 0.7 mm in length. Then we created the end-to-side anastomosis (common carotid artery end to jugular vein side) using 11-0 nylon heel-to-toe continuous suturing. We unclamped the vessels and checked for patency (Figure 1, A and B).

Three weeks after AV fistula creation, we euthanized the animals, and the AV anastomoses were perfusion-fixed via the left ventricle at 100 mmHg pressure as described previously. Before perfusion fixation, we drew blood from the left ventricle for the biochemical analysis. BUN, phosphorus, and calcium were measured by autoanalyzer techniques in the Animal Facility Clinical Laboratory at Washington University in St. Louis, Missouri. We measured mouse serum OPN by ELISA kit purchased from Assay Designs, Ann Arbor, Michigan.

Immunohistochemistry and Histomorphometry
We harvested the jugular vein and the left common carotid artery adjacent to the anastomosis at the time of sacrifice. Samples were processed and embedded in paraffin. We obtained serial sections of 5-μm thickness every 100 μm throughout the AV anastomosis (Figure 1, C to F) or the entire left common carotid artery (ligation injury), and we stained them with Verhoeff elastic-van Gieson (VvG) and hematoxylin and eosin (H&E). For immunohistochemistry, adjacent sections were stained for SMC (SM α-actin, 1:500 dilution; Sigma-Aldrich, St. Louis, Missouri) and PCNA (1:1000 dilution; Santa Cruz Biotech, Santa Cruz, California) as described previously. For immunohistochemistry, adjacent sections were stained for SMC (SM α-actin, 1:500 dilution; Sigma-Aldrich, St. Louis, Missouri) and PCNA (1:1000 dilution; Santa Cruz Biotech, Santa Cruz, California) as described previously. We performed volumetric measurements for NH lesion and thrombus on digitizing images using Olympus Microsuite software (Olympus Soft Imaging Solutions, Lakewood, Colorado). First, we determined the luminal border of the anastomosis with VvG staining of the internal elastic lamina. Second, SMCs and surrounding extracellular matrix stain could be distinguished from thrombus with nuclear and collagen staining of H&E and overlapping staining of SM-specific α-actin. Inflammatory cells (neutrophils and macrophages) and thrombus did not stain for SM-specific α-actin (brown) and collagen (pink on H&E).

All anastomoses had four to five 100-μm sections. We used all sections, including the anastomotic and peri-anastomotic segments, to determine the total anastomotic NH lesion volume. We easily identified the NH lesion borders by the lumen and the internal elastic lamina and the cells staining for SM-specific α-actin. We calculated the total NH lesion volume with the summation of consecutive sections and multiplied them by 100 μm (distance between sections). Similarly, we calculated the anastomotic and peri-anastomotic thrombus volume from each cross-section and compared them between CKD and sham animals.

Cellular Proliferation Rate Calculation
The PCNA technique is as described previously in our laboratory. In short, we selected two adjacent anastomotic cross-sections with the largest NH lesion formation from every CKD and sham animal harvested at 1, 2, and 3 wk after fistula creation. We counted all of the nuclei (denominator) in the NH lesion with H&E staining and counted the nuclei stained for PCNA (nominator) to determine the percentage of cellular proliferation (mean ± SD). We then compared the percentage of proliferation between CKD and sham animals at each time point.

Photochemically Induced Carotid Artery Thrombosis in Mice
We followed the protocol of Eitzman et al. with slight modifications. The CKD and sham animals were anesthetized with pentobarbital, secured in the supine position, and placed under a dissecting microscope. Following a midline cervical incision, the right common carotid artery was isolated, and we applied a Doppler flow probe (model 0.5 VB; Transonic Systems, Ithaca, New York). We induced thrombosis by an injection of rose bengal dye (Fisher Scientific, Pittsburgh, Pennsylvania) into the tail vein in a volume of 120 μl at a concentration of 50 mg/kg using a 29-gauge needle. Just before injection, we applied a 1.5 mW, 540 nm green light laser (Melles Griot, Carlsbad, California) to the desired site of injury from a distance of 6 cm. The laser remained on until thrombosis occurred. We monitored flow in the vessel with the Doppler probe for 150 min from the onset of injury, at which time the animal was humanely killed.

Irradiation and Bone Marrow Transplantation with GFP Mouse
GFP mouse are transgenic mice that ubiquitously express enhanced GFP. GFP and wild-type (C57BL/6) mice underwent lethal gamma irradiation (approximately 9.5 Gy) from a cesium source, followed 6 h later by transplantation with femoral bone marrow cells obtained from 10-wk-old GFP donors (5 × 10^7 cells per recipient; 0.3 to 0.5 ml volume by retro-orbital injection) as described previously. The animals were housed in a specific pathogen-free barrier environment.
All nontransplanted mice died 7 to 14 d after irradiation. After 6 wk, animals achieving successful bone marrow transplantation underwent renal ablation and AV fistula creation. Three weeks later, we sacrificed the animals for histomorphometric analyses.

Ex Vivo VSMC Migration Assay
Type I collagen acid extracted from rat tail tendons (Sigma-Aldrich) was dissolved in 0.2% acetic acid to a final concentration of 2.7 mg/ml.40 Before the assay, fragments of mouse thoracic aorta from CKD and sham mice were stripped of intima and adventitia, and the media of the vessel wall was dissected into 1 × 1-mm fragments. Media explants from CKD and sham mice were then suspended within a solution of type I collagen and were cultured for 7 d in Dulbecco’s modified Eagle’s medium supplemented with 20% autologous CKD and sham mouse sera, respectively. We quantified migratory activity by measuring the distance migrated by the leading front of VSMC from the explanted tissue. For proliferation-free VSMC migration, we added 5 mM hydroxyurea to the media.

Statistical Analysis
Results are shown as mean ± one SD. Excel 2003 statistical package was used for the quantitative analysis of parameters such as NH lesion and thrombus volume (t test). P values less than 0.05 were considered significant.

ACKNOWLEDGMENTS
Oral presentation of this report was given at the American Society of Nephrology meeting (Renal week 2007), October 31–November 5, 2007, San Francisco, California. This research was supported in part by National Institutes of Health grant HL-68119 (to E.T.C.), and by the Wylie Scholar Award (to E.T.C.) from the Pacific Vascular Research Foundation. Dr. Choi is affiliated with the John Cochran Veterans Administration Hospital in St. Louis, Missouri. We want to thank Dr. Douglas Tollefsen, Dr. Robert Mecham, and Mr. Russell Knutsen for their assistance with carotid occlusion experiments and BP measurements.

DISCLOSURES
None.

REFERENCES


Supplemental information for this article is available online at http://www.jasn.org/.